Gastroenterology
Volume 135, Issue 5 , Pages 1552-1560 , November 2008

Portal Hypertension and Primary Biliary Cirrhosis: Effect of Long-Term Ursodeoxycholic Acid Treatment

  • Pierre–Michel Huet

      Affiliations

    • Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Québec, Canada
    • INSERM Unité 568, Liver Unit, Hôpital l'Archet 2, Université de Nice-Sophia Antipolis, Nice, France
    • Corresponding Author InformationAddress requests for reprints to: Pierre–Michel Huet, MD, PhD, Domaine de la Bastide (No7), 442 Route de l'Aire Saint-Michel, 06950, Falicon, France
    • ,
  • Catherine Vincent

      Affiliations

    • Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Québec, Canada
    • ,
  • Julie Deslaurier

      Affiliations

    • Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Québec, Canada
    • ,
  • Jean Coté

      Affiliations

    • Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Québec, Canada
    • ,
  • Shoichi Matsutami

      Affiliations

    • Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Québec, Canada
    • ,
  • Robert Boileau

      Affiliations

    • Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Québec, Canada
    • ,
  • Jacline Huet–van Kerckvoorde

      Affiliations

    • Centre de Recherche, Centre Hospitalier de l'Université de Montréal, Hôpital Saint-Luc, Montréal, Québec, Canada

Received 27 November 2007 ,Accepted 17 July 2008.

References 

  1. Xu B, Broome U, Uzunel M, et al. Capillarization of hepatic sinusoid by liver endothelial cell-reactive autoantibodies in patients with cirrhosis and chronic hepatitis. Am J Pathol. 2003;163:1275–1298
  2. Zeegen R, Stansfeld AG, Dawson AM, et al. Bleeding oesophageal varices as the presenting feature in primary biliary cirrhosis. Lancet. 1969;2:9–13
  3. Lebrec D, Sicot C, Degott C, et al. Portal hypertension and primary biliary cirrhosis. Digestion. 1976;14:220–226
  4. Boyer T, Triger DR, Horisawa M, et al. Direct transhepatic measurement of portal vein pressure using a thin needle (Comparison with wedged hepatic vein pressure). Gastroenterology. 1977;72:584–589
  5. Pomier-Layrargues G, Kusielewiicz D, Willems B, et al. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology. 1985;5:415–418
  6. Kew MC, Varma RR, Dos Santos HA, et al. Portal hypertension in primary biliary cirrhosis. Gut. 1971;12:830–834
  7. Navasa M, Parés A, Bruguera M, et al. Portal hypertension in primary biliary cirrhosis (Relationship with histological features). J Hepatol. 1987;5:292–298
  8. Gores G, Wiesner RH, Dickson ER, et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology. 1989;96:1552–1559
  9. Poupon R, Chrétien Y, Poupon RE, et al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet. 1987;1:834–836
  10. Heathcote EJ. Management of primary biliary cirrhosis (The American Association for the Study of Liver Diseases practice guidelines). Hepatology. 2000;31:1005–1013
  11. Poupon RE, Balkau B, Escwège E, et al. UDCA-PBC Study Group A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548–1554
  12. Lindor KD, Dickson ER, Baldus WP, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284–1290
  13. Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149–1156
  14. Combes B, Carithers RL, Maddrey WC, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759–766
  15. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology. 1997;113:884–890
  16. Goulis J, Leandro G, Burroughs AK. Randomized controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999;354:1053–1060
  17. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997;72:1137–1140
  18. Combes B, Luketic VA, Peters M, et al. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol. 2004;99:264–268
  19. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103–112
  20. Coperchot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000;32:1196–1199
  21. Murray KF, Carithers RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407–1432
  22. Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model established its generalizability. Hepatology. 1989;10:846–850
  23. Abraldes JG, Tarantino I, Turnes J, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long term prognosis of cirrhosis. Hepatology. 2003;37:902–908
  24. Parés A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715–720
  25. Van Hoogstraten HJF, Hansen BE, van Buuren HR, et al. Dutch Multi-Centre PBC Study Group Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. J Hepatol. 1999;31:256–262
  26. Leuschner M, Dietrich CF, You T, et al. Characterisation of patients with primary biliary cirrhosis responding to long-term ursodeoxycholic acid treatment. Gut. 2000;46:121–126
  27. Jorgensen R, Angulo P, Dickson ER, et al. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. Am J Gastroenterol. 2002;97:2647–2650
  28. Chan CW, Gunsar F, Feudjo M, et al. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther. 2005;21:217–226
  29. Coperchot C, Poujol-Robert A, Wendum D, et al. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary cirrhosis. Liver Int. 2004;24:187–193
  30. Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol. 2005;43:951–957
  31. Coperchot C, Carrat F, Dahr A, et al. The effect of ursodeoxycholic acid on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297–303
  32. Ter Borg PCJ, Schalm S, Hansen BE, et al. Dutch PBC Study Group Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis (Results of a 10-yr cohort study involving 297 patients). Am J Gastroenterol. 2006;101:2044–2050
  33. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847

 S.M's current affiliation is: Chiba College of Health Science, Chiba, Japan.

 The authors disclose the following: Supported in part by a university/industry grant from the National Research Council of Canada and Interfalk Canada (1988–1991) and by an unrestricted grant from Jouveinal Canada (1991–1995).

 None of the authors have any conflict of interest to disclose with companies making the concerned or a competing product. The authors were collectively responsible for the study design, data collection, statistical analysis, and interpretation of data; the writing of the manuscript; and the decision to submit the manuscript for publication. There was no writing assistance.

PII: S0016-5085(08)01329-2

doi: 10.1053/j.gastro.2008.07.019

Gastroenterology
Volume 135, Issue 5 , Pages 1552-1560 , November 2008

Article Tools

* Image Usage & Resolution